Meia-vida após doses
- Created by
- Renato Passos, Eng. de Software
- Reviewed by
- Renato Passos, Eng. de Software
Last updated: Apr 18, 2026
About this calculator
The 'Half-life after Doses' calculator estimates the time required for a drug to reach steady-state plasma concentration after multiple doses. It uses the drug's half-life (t½) and the number of administered doses to calculate accumulation intervals. Each subsequent dose contributes to increasing plasma concentration until a steady state is achieved.
The calculation is based on the principle that after each half-life, 50% of the drug is eliminated. With 5 half-lives, approximately 97% of the steady-state concentration is reached. The formula considers the exponential summation of dose effects to predict total accumulation, helping to plan safe dosing intervals.
This tool is valuable in clinical pharmacology for adjusting therapeutic regimens. For example, in patients with renal or hepatic impairment, where drug half-life may prolong. It also helps prevent toxicity from overdosing by ensuring therapeutic levels are achieved without exceeding toxic thresholds.
Note that this calculation is a mathematical approximation. Factors like individual metabolic variability, drug interactions, and non-oral administration routes can alter real-world results. Always consult a healthcare professional for clinical decisions.
Frequently asked questions
Why do 5 half-lives correspond to 97% accumulation?
Each half-life reduces remaining concentration by 50%. After 5 cycles, the exponential decay sum reaches ~97% of steady-state concentration.
Does this work for all drugs?
It's an idealized model. Drugs with nonlinear kinetics (e.g., phenytoin) or enzyme induction/inhibition may need manual adjustments.
How does this affect dosing frequency?
It indicates the minimum interval between doses to prevent toxicity, but doesn't replace specific clinical analyses.
Can I use this for drug discontinuation calculations?
No. This tool focuses on accumulation from consecutive doses, not elimination after discontinuation.
Should I consider other factors besides half-life?
Yes: volume of distribution, renal/hepatic clearance, and drug interactions may alter real-world results.